Understand the source comparison
Survodutide vs Existing NASH Therapies: A Mechanistic Comparison
Survodutide 4.8mg Dual GLP-1/glucagon receptor agonist 83% (Phase 2b, 48 weeks) 47% (≥1 stage reduction) 72.8% Highest resolution rate to date; dual mechanism addresses lipid metabolism and inflammation concurrently Semaglutide 2.4mg GLP-1 receptor agonist 59%
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide 4.8mg
- Dual GLP-1/glucagon receptor agonist
- 83% (Phase 2b, 48 weeks)
- 47% (≥1 stage reduction)
- 72.8%
- Highest resolution rate to date; dual mechanism addresses lipid metabolism and inflammation concurrently
- Semaglutide 2.4mg
- GLP-1 receptor agonist
- 59% (Phase 2, 72 weeks)
- 43% (≥1 stage reduction)
- ~50%
- Proven efficacy but lower resolution vs dual-agonists; no direct hepatic glucagon signaling
- Resmetirom 80mg
- Thyroid hormone receptor-beta agonist
- 30% (Phase 3 MAESTRO-NASH)
- 26% (≥1 stage reduction)
- 36.8%
- Targets hepatic lipid synthesis but lacks systemic metabolic benefits; lower efficacy than incretins
- Tirzepatide 15mg
- GLP-1/GIP dual agonist
- Data pending (Phase 2 ongoing)
- Not yet reported
- Estimated 60–70%
- GIP receptor lacks glucagon's direct lipolytic effect in hepatocytes; strong weight loss but unclear fibrosis impact
- The comparison reveals why Survodutide's mechanism matters. Resmetirom targets only hepatic thyroid receptors. It reduces lipogenesis but doesn't accelerate oxidation or improve whole-body insulin sensitivity. Semaglutide improves metabolic parameters systemically but lacks the direct hepatic lipid clearance that glucagon receptor activation provides. Tirzepatide combines GLP-1 with GIP (glucose-dependent insulinotropic polypeptide), which enhances insulin secretion and adipocyte function but doesn't replicate glucagon's hepatic cAMP-driven lipolytic cascade. Survodutide occupies a mechanistic niche that existing therapies do not.